JPMorgan Chase & Co. Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price

Key Points

• JPMorgan lowered Abbott’s price target from $120 to $118 but maintained an “overweight” rating, implying 17.32% upside from the stock’s previous close.
• Analyst sentiment remains favorable: Abbott has a consensus “Moderate Buy” rating and an average price target of $117.84, despite several firms recently reducing their targets.
• Abbott’s latest quarter included $1.42 in adjusted EPS and $13.01 billion in revenue, while investors remain focused on weaker medical-device momentum and the planned tax-free spin-off of its roughly $8.5 billion Nutrition business by the end of 2027.

Abbott Laboratories (NYSE:ABT - Get Free Report) had its price target cut by stock analysts at JPMorgan Chase & Co. from $120.00 to $118.00 in a research note issued on Thursday, Benzinga reports. The firm presently has an "overweight" rating on the healthcare product maker's stock. JPMorgan Chase & Co.'s target price would suggest a potential upside of 17.32% from the stock's previous close.

Other analysts also recently issued reports about the stock. Wolfe Research raised shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price target for the company in a research note on Thursday, August 13th. Citigroup boosted their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a research report on Friday, July 17th. UBS Group decreased their target price on shares of Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, July 28th. BTIG Research decreased their price objective on shares of Abbott Laboratories from $134.00 to $125.00 and set a "buy" rating on the stock in a research report on Thursday. Finally, Piper Sandler reiterated an "overweight" rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $117.84.

Abbott Laboratories Price Performance

ABT traded up $0.07 during trading on Thursday, reaching $100.58. The stock had a trading volume of 742,079 shares, compared to its average volume of 11,279,271. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The stock has a market cap of $174.04 billion, a PE ratio of 32.40, a PEG ratio of 1.90 and a beta of 0.59. The business has a 50-day moving average of $105.47 and a 200-day moving average of $98.28. Abbott Laboratories has a one year low of $81.97 and a one year high of $132.02.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, meeting analysts' consensus estimates of $1.42. The company had revenue of $13.01 billion for the quarter, compared to analysts' expectations of $12.99 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. Abbott Laboratories's revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period last year, the firm posted $1.30 EPS. As a group, equities research analysts anticipate that Abbott Laboratories will post 5.53 EPS for the current fiscal year.

Hedge Funds Weigh In On Abbott Laboratories

A number of institutional investors have recently added to or reduced their stakes in the company. Ledyard National Bank lifted its position in Abbott Laboratories by 6.4% during the 3rd quarter. Ledyard National Bank now owns 15,237 shares of the healthcare product maker's stock valued at $1,506,000 after acquiring an additional 913 shares during the period. Culbertson A N & Co. Inc. grew its holdings in Abbott Laboratories by 0.3% in the third quarter. Culbertson A N & Co. Inc. now owns 90,195 shares of the healthcare product maker's stock worth $8,914,000 after purchasing an additional 270 shares during the period. NBT Bank N.A. bought a new position in shares of Abbott Laboratories during the third quarter valued at approximately $9,060,000. Root Financial Partners LLC increased its stake in shares of Abbott Laboratories by 93.7% during the third quarter. Root Financial Partners LLC now owns 7,430 shares of the healthcare product maker's stock valued at $734,000 after purchasing an additional 3,594 shares in the last quarter. Finally, Precedent Wealth Partners LLC lifted its holdings in shares of Abbott Laboratories by 10.7% during the third quarter. Precedent Wealth Partners LLC now owns 33,354 shares of the healthcare product maker's stock valued at $3,296,000 after purchasing an additional 3,234 shares during the last quarter. Institutional investors own 75.18% of the company's stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported third-quarter adjusted earnings of $1.42 per share, in line with the broader consensus, while revenue of $13.01 billion slightly exceeded the $12.99 billion estimate. Reported sales increased 14.5% year over year, and comparable sales rose 7%. Abbott Reports Third-Quarter 2026 Results
• Positive Sentiment: The company reaffirmed its full-year adjusted EPS guidance, while highlighting new product approvals and margin expansion. The results also showed year-over-year EPS growth from $1.30 to $1.42. Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
• Positive Sentiment: Robert W. Baird raised its ABT price target from $121 to $123 and maintained an “outperform” rating. BTIG lowered its target from $134 to $125 but retained a “buy” rating; both targets imply substantial upside from the reference price. Benzinga Analyst Actions
• Neutral Sentiment: Abbott intends to execute a tax-free spin-off of its approximately $8.5 billion Nutrition business, including Similac, Ensure and Pedialyte, by the end of 2027. Management expects the separation to sharpen strategic focus and improve Abbott’s growth and margin profile, but investors must assess execution and the eventual standalone businesses. Abbott Nutrition Spin-Off Announcement
• Negative Sentiment: Abbott reduced its 2026 sales-growth forecast, citing weakness in medical devices. That outlook revision overshadowed the revenue beat and raised concerns about near-term momentum. Abbott Lowers 2026 Sales Growth Forecast
• Negative Sentiment: Some analysts characterized adjusted EPS as a modest miss against a $1.43 estimate, adding to the cautious reaction. The Nutrition separation also introduced uncertainty and contributed to selling pressure despite strong headline growth. ABT Stock Down After Third-Quarter Results

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.